The Evidence for Galleri®: CCGA, PATHFINDER and NHS-Galleri

15.10.2026 17 min

We talk about the numbers as they are — without exaggeration.

The audio for this episode is coming soon.

This episode may have been prepared with AI assistance; it may contain gaps or phrasing errors. It is for general information only and does not constitute medical advice. For your health decisions, please consult your physician or the Omega Genetik center.

About the Episode

CCGA (15,254 participants), PATHFINDER 1 and 2, and the NHS-Galleri randomized trial: this episode covers the clinical evidence base for Galleri®. We explain specificity, sensitivity, positive predictive value and stage-dependent sensitivity differences in everyday language, and discuss what the numbers do and do not say.

Our goal: the listener understands test performance in a realistic frame.

#galleri #kanıtlar

Rx-only — prescription screening test. Galleri® is not a diagnostic test. A positive result does not mean a cancer diagnosis; a negative result does not rule out cancer. The test does not replace the routine cancer screenings recommended by your physician. Galleri® does not detect all cancers.